Author: admin

Rexburg Carpet Cleaners Provides Extra Service For Homes With Pets

Homes where pets are a member of the family often struggle with maintaining a clean and odor-free carpet. The technicians have the knowledge and tools to provide safe solutions.

Kaboom Carpet Cleaners and Jason Rennaker are pleased to announce that the expert carpet technicians are trained in handling pet-related carpet issues with precision and care. Whether it is removing stubborn pet stains, neutralizing odors, or addressing allergens associated with pet dander, the Rexburg carpet cleaners have the expertise and advanced solutions to restore the freshness and cleanliness of the carpets. Pet and odor treatment is a necessary step when pets are part of the household. The living spaces need products and methods that are non-toxic and effective. A little extra service is required to remove stains and odors in households with pets such as cats or dogs.

Odor removal, particularly for pet odors, typically involves a multi-step process designed to eliminate the source of the odor rather than simply masking it. The technician may apply a pre-treatment solution specifically formulated to break down and neutralize the odor-causing molecules.

This solution often includes enzymes that target organic matter like urine, feces, or pet dander. After the pre-treatment has had time to work, the technician proceeds with the cleaning process, which could involve hot water extraction (steam cleaning) or another appropriate method for the carpet type. An additional odor-neutralizing agent may be applied after cleaning to ensure that any remaining odor molecules are neutralized. These agents work to alter the odor molecules, rendering them odorless chemically.

Further details are available at https://kaboomcarpetcleaners.com/

The expert technicians are trained in handling pet-related carpet issues carefully. Whether it is removing stubborn pet stains, neutralizing odors, or addressing allergens associated with pet dander, Kaboom Carpet Cleaners has the expertise and advanced solutions to restore the freshness and cleanliness of carpets. It is vital to note that the effectiveness of odor removal depends on factors such as the age of the odor, the type of odor, and the cleanliness of the affected area. Fresh stains and odors are generally easier to eliminate than older ones, and severe or deeply embedded odors may require multiple treatments.

Prompt action on stains, regardless of the type, is essential. Don’t wait until it is too late. Fresh stains have a better chance of being eradicated. Older or deep-rooted stains may penetrate beneath the carpet into the subfloor, making it nearly impossible to remove entirely.

Cleaning carpets as a do-it-yourself project is a preferred way to save money, but it is impossible to match a professional-level cleaning in a DIY setting. The right equipment, knowledge, and techniques can help leave carpets as fresh as possible. Some of the benefits of a professional carpet clean include high-temperature steam clean (up to 300 degrees), a powerful truck-mounted vacuum system, hoses and wands to penetrate deeper into the carpets, professional pre-treatment solutions, and better drying times, thanks to better extraction and air movers.

Booking a session with the professional team is easy and convenient. The website includes contact information so customers can identify the areas to be cleaned and any additional services that need to be addressed. Carpets can be in rooms throughout the house, as well as on hallways and stairs. If there are areas that are high traffic, a pre-treatment may be suggested so the entire carpeted surface looks and smells clean.

The technicians are knowledgeable and trained to give customers the best possible results. They are dedicated to customer satisfaction for each cleaning project. Questions or concerns about specific issues can be addressed before the cleaning process begins.

About the Company:

Kaboom Carpet Cleaners offers deep carpet cleaning for homeowners in the Rexburg area. The technicians know how to take care of general cleaning, as well as pet stains and odors. Additional services can be arranged online or by direct contact.

Media Contact
Company Name: Kaboom Carpet Cleaners
Contact Person: Jason Rennaker
Email: Send Email
Phone: (208) 656-4992
Address:23 S 1st East
City: Rexburg
State: ID 83440
Country: United States
Website: https://kaboomcarpetcleaners.com/

Timepie collaborates with Zhejiang Institute of Tianjin University (Shaoxing) to promote the world’s first commercial mass production of “longevity bacteria” AKK

On December 8, 2023, Timepie’s TimeCure Comprehensive Anti-Aging Center partnered with Zhejiang Institute of Tianjin University (Shaoxing) to jointly advance the research and screening of new anti-aging substances, as well as the transformation of scarce anti-aging components, and held the global first commercial production release conference for the longevity bacteria AKK.

Representatives from Timepie and the Zhejiang Institute of Tianjin University (Shaoxing) attended the event.

The longevity bacteria AKK, as a hot topic in the health field, has long been the focus of attention from various quarters. AKK can regulate immune responses in the spleen, intestines, and mesenteric lymph nodes, and is negatively correlated with symptoms of enteritis, obesity, diabetes, and cardiovascular metabolic diseases. Based on international research achievements, the Zhejiang Institute of Tianjin University (Shaoxing) has achieved a breakthrough in the transformation of the longevity bacteria AKK from laboratory sample research to mass production.

Zhejiang Institute of Tianjin University (Shaoxing)

Since the strategic cooperation began in March between Timepie and the Zhejiang Institute of Tianjin University (Shaoxing), Timepie has been closely monitoring the progress of the AKK mass production experiment and providing comprehensive support. In this collaboration, the research institute and Timepie will work together to promote a series of anti-aging substances, including the research and screening of new anti-aging substances and the transformation of scarce anti-aging components, with a total agreement amounting to tens of millions.

At the release conference, the leader of Timepie expressed heartfelt congratulations on the research results of the “longevity bacteria” AKK by the Zhejiang Institute of Tianjin University (Shaoxing), and shared,

“Currently, it is found that almost all cutting-edge anti-aging therapies face issues such as slow transformation speed and resource competition. During the pandemic, we have opened anti-aging and anti-epidemic components to readers repeatedly at no cost. However, due to limited resources and capabilities, we are unable to benefit everyone. In response to this, we hope that through this collaboration, more people can have the opportunity for healthy longevity.”

Founded in early 2019, Timepie has become a member of the China Anti-Aging Promotion Association and the first comprehensive aging management service platform in China. It is dedicated to the field of longevity technology, aiming to promote healthy aging in humans. It has self-funded the establishment of a biopharmaceutical team with backgrounds from universities at home and abroad, maintaining high-intensity resource input to share cutting-edge anti-aging knowledge with the public and engage in the longevity industry. It has never considered commercializing scientific research results for its own benefit, but has always taken the most fair and objective stance towards cutting-edge anti-aging research, aiming to promote the building of a human health community.

The mass production technology of the AKK may trigger a new wave of “commercial frenzy,” and Timepie is willing to transfer the research results of commercial production for the innovation research of Timepie and Zhejiang Institute of Tianjin University (Shaoxing), promoting the sustainable development of anti-aging research. Future plans will also include the establishment of scholarships at Tianjin University and other high-level schools, the formation of scientific teams, assessment, and funding of more anti-aging scientific research projects.

Timepie has always been willing to attempt and has successfully held three consecutive global aging intervention forums, bringing together global experts, scholars, longevity industry investors and entrepreneurs, anti-aging enthusiasts, and others to explore the latest developments, cutting-edge technology, and industry dynamics in aging intervention. The fourth global aging intervention forum will also kick off on December 9, and Timepie is looking forward to more collaborations, while providing investment and funding, showcasing the progress and determination made by China in the anti-aging cause.

As the release conference came to a successful close, for the currently highly watched anti-aging field in China, the “longevity bacteria” AKK has successfully entered the public’s view. It is believed that in the near future, numerous AKK products will appear in the public view, bringing great help to those in need of anti-aging solutions.

Media Contact
Company Name: Time International Holding Limited
Email: Send Email
State: Hongkong
Country: China
Website: https://www.timepie.com/

HedgeFundBank and Major Commercial Banks’ Global Alliance, Expected to Lead a Transformation in the Financial Services Industry

On November 23, the financial fund platform HedgeFundBank plans to become a global strategic partner with major commercial banks, establishing a financial fund platform service alliance to promote global industry development and provide high-quality service solutions to customers. This initiative marks the exploration of a new model in fund investment by international financial institutions, potentially leading to significant changes in the investment methods of these institutions.

As an industry leader, HedgeFundBank has been providing world-class services since its establishment in 2017, attracting attention from the market and media. It has been rated as investment-grade BBB by Standard & Poor’s. The company serves more than 200 banks and securities dealers, and over 400 financial intermediary institutions in over 80 countries and regions, offering trading investment services and solutions. It has processed an annual cumulative transaction volume exceeding one hundred billion, establishing a convenient, stable, and practical brand image among institutional investors.

To date, HedgeFundBank has signed distribution agreements with brand funds in various global partner regions, selecting the best from online financial products, and collaborating with globally renowned investment research, rating, and consulting organizations to recommend the most authoritative data and analysis reports to the most suitable investors. Meanwhile, several stable banks in the international market serve as the supervisory banks for HedgeFundBank’s fund sales, ensuring safe and stable transactions for investors.

If HedgeFundBank successfully establishes global strategic partnerships with major commercial banks, it will provide a new one-stop investment advisory service for a wide range of financial institution clients. HedgeFundBank has already launched various composite strategies on its platform, such as wealth management alternatives, to meet the diverse risk preferences and investment horizons of financial institutions. The Market Department Manager of HedgeFundBank stated that besides the strategies already launched, HedgeFundBank can also offer customized strategies based on the needs of institutional clients.

HedgeFundBank’s specialty lies in helping investors choose suitable wealth management products and providing professional investment and wealth management services. The company is fully committed to building a leading global wealth management O2O model, promoting an upgrade of the original business model. Investing in wealth management on online financial platforms, ordinary people can not only receive professional investment advisory guidance but also enjoy the convenience of one-stop wealth management, realizing functions like online reservation, transaction, and payment of funds and other financial products, achieving stable wealth appreciation.

It is reported that on the first day HedgeFundBank announced its cooperative strategy, bank clients signed contracts and transferred funds, operating the system smoothly and efficiently. In light of this, HedgeFundBank will establish alliances with more partners, enhancing market competitiveness, providing customers with more choices, and striving to become the most trusted financial assistant for investors.

Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: HedgeFundBank
Contact Person: Sophia Brown
Email: Send Email
Country: United States
Website: https://hedgefundbank.com/

JR Spear Hosted Business Leaders Network Live Mastermind

Orlando, FL, USA – December 12, 2023 – JR Spear, a renowned entrepreneur and thought leader in the business world brought together industry leaders and 12 nationally recognized speakers to Orlando, FL to spark innovation, elevated leadership, and success amongst his community, the Business Leaders Network (BLN). This event was a game-changer for business professionals looking to network, learn, and elevate their careers to new heights.

The BLN Live Mastermind, spearheaded by JR Spear, is a unique and exclusive opportunity for entrepreneurs, executives, and business enthusiasts to come together, share knowledge, and collaborate on groundbreaking ideas. The next event hosted by the Business Leaders Network will take place in Washington, DC January 18-19, 2024.

Spear is a widely recognized business strategist, author, and public speaker with a remarkable track record in helping companies achieve exceptional growth. With a passion for fostering innovation and sharing his wealth of knowledge, JR Spear is the perfect host for this prestigious event. Spear’s mission is to grow a nationwide community of servant leaders.

Key highlights of the BLN Live Mastermind event included:

• World-Class Speakers: Attendees heard from industry leaders and renowned speakers who shared their insights, strategies, and success stories.

• Networking Opportunities: The event provided a platform for attendees to connect with like-minded individuals, fostering valuable professional relationships.

• Interactive Workshops: JR Spear and other experts conducted hands-on workshops and engaged participants in interactive discussions, enabling them to apply the lessons learned in their businesses.

• Panel Discussions: Engaging panel discussions explored the latest trends, challenges, and opportunities in today’s ever-evolving business landscape.

• Exclusive Resources: Attendees gained access to a wealth of resources, tools, and insights that will help them excel in their respective fields.

JR Spear’s commitment to excellence and the success of his attendees ensured that the BLN Live Mastermind was a transformative experience for all who participated.

JR Spear expressed his enthusiasm for all BLN Live events, saying, “I am thrilled to host the BLN Live Mastermind in Orlando and our next BLN Live Event in Washington, DC. It’s an opportunity for individuals and businesses to come together, learn, grow, and inspire one another. I believe in the power of collaboration and innovation, and this event will be a catalyst for achieving remarkable success.”

Tickets for the BLN Live Entrepreneur Summit in Washington, DC January 18-19th can be purchased at www.BLNLive.com. Early registration for the January 2024 BLN Live Event is encouraged as space for these exclusive events is limited. For more information and to learn more about the Business Leaders Network, visit www.BLNCommunity.com.

About JR Spear

JR Spear is the founder of CREED Consulting, Business Leaders Network, and the host of the Daily Creed Podcast. As a U.S. combat veteran, JR survived a suicide bombing ambush that gave him a renewed sense of purpose, leading to multiple businesses’ success. Dedicated to empowering small business owners and inspiring servant leaders, he’s created a comprehensive platform dedicated to helping authors, speakers, coaches, and small business owners make more money by finding more and better leads for their businesses.

JR is the author of The Success Guide to Building Your Coaching Empire. This book focuses on breaking limited beliefs that keep individuals from achieving personal and professional success, helping entrepreneurs gain clarity and confidence to attract the perfect clients and achieve success. Follow JR Spear at www.BLNCommunity.com.

Media Contact
Company Name: Vedette Global Media
Contact Person: Angel Tuccy
Email: Send Email
Phone: 720-257-9263
Country: United States
Website: https://vedettenews.com

US Housing Consultants Names Dan Biron Executive Vice President Of Inspection Services

US Housing Consultants Names Dan Biron Executive Vice President Of Inspection Services

Dan Biron is US Housing Consultants’ new Executive Vice President of Inspection Services.

“Dan has been an integral part of the inspection team for over 17 years and has become a recognized leader in the industry on REAC protocol, both UPCS and the new NSPIRE standards,” says US Housing Consultants’ Chief Executive Officer Jim Campanella.

“In his new role,” Campanella concludes, “Dan will work with the inspection services team to lead the industry in guiding our clients to ensure compliance of NSPIRE standards.”

With the recent rollout of NSPIRE, the affordable housing industry is faced with new challenges and the need for leadership is great. NSPIRE’s new physical inspection requirements are a new way of thinking that everyone from executives to property managers, professional inspectors, and maintenance professionals need to understand. Those accustomed to conducting HQS and UPCS Inspections must understand the step-by-step requirements of what makes something a deficiency.

These new challenges are far from insurmountable, and US Housing Consultants believes that Biron’s leadership and expertise will help our company and our clients work together through this period of relative uncertainty.

“I am excited to take on the challenge of leading our Inspection Services department,” Biron says, “and look forward to serving our team and clients. During my time with US Housing Consultants, I have had the pleasure of working with countless passionate people who share the mission to improve the quality of affordable housing in this country.”

US Housing Consultants offers several NSPIRE-related services, from pre-REAC inspections to online or hands-on training.

Media Contact
Company Name: USHC
Contact Person: Media Contact
Email: Send Email
Country: United States
Website: http://www.us-hc.com

Cholangiocarcinoma Pipeline Drugs Analysis Report(2023 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Merck KGaA, Eisai, Janssen Research, 3D Medicines, Basilea Pharma

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Cholangiocarcinoma pipeline constitutes 55+ key companies continuously working towards developing 60+ Cholangiocarcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Cholangiocarcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Cholangiocarcinoma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cholangiocarcinoma Market.

 

Some of the key takeaways from the Cholangiocarcinoma Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Cholangiocarcinoma treatment therapies with a considerable amount of success over the years. 
  • Cholangiocarcinoma companies working in the treatment market are Well Marker Bio, Sirnaomics, Kinnate Biopharma, Medivir, Eisai Co., Ltd., TransThera Biosciences, Hutchison Medipharma Limited, RedHill Biopharma Limited, Compass Therapeutics, Merck Sharp & Dohme, Eisai, Merck & Co, Zymeworks and BeiGene, Decalth Systems, Basilea Pharmaceutica, AstraZeneca, Taiho Oncology, and others, are developing therapies for the Cholangiocarcinoma treatment 
  • Emerging Cholangiocarcinoma therapies in the different phases of clinical trials are- WM-S1, STP-705, KIN-3248, MIV-818, E7090, TT-00420, HMPL-453, ABC294640, CTX-009, KEYTRUDA (pembrolizumab), Tasurgratinib (E7090), LENVIMA (lenvatinib), Zanidatamab, Melphalan, Derazantinib, Imfinzi (durvalumab), TAS-120 (futibatinib), and others are expected to have a significant impact on the Cholangiocarcinoma market in the coming years.   
  • In May 2023, Richard Kim discussed the investigation of RLY-4008 as a treatment for individuals diagnosed with cholangiocarcinoma possessing an FGFR2 fusion or rearrangement. RLY-4008, an exceptionally selective and irreversible FGFR2 inhibitor, is presently undergoing assessment in the phase 1/2 REFOCUS trial (NCT04526106). Initial data presented at the 2022 ESMO Congress revealed that among patients with FGFR inhibitor–naïve cholangiocarcinoma and an FGFR2 fusion or rearrangement (n = 17), there was an observed overall response rate of 88.2%.
  • In April 2023, Nuvectis Pharma shared key findings from the poster presentation of NXP800 during the American Association for Cancer Research (“AACR”) Annual Meeting 2023 held in Orlando, FL. The strong preclinical efficacy displayed by NXP800 in cholangiocarcinoma patient-derived xenograft (PDX) models is seen as a promising sign for potential clinical advantages. Cholangiocarcinoma is notably challenging to treat, often resulting in unfavorable outcomes, and these recent findings offer hope for future treatment prospects for patients.
  • In April 2023, Verismo Therapeutics has been granted fast-track designation by the US Food and Drug Administration (FDA) for its investigational new drug, SynKIR-110. SynKIR-110 is an experimental medication aimed at addressing severe diseases and life-threatening conditions, specifically targeting mesothelin-expressing mesothelioma, ovarian cancer, and cholangiocarcinoma.
  • In January 2023, Taiho Oncology, Inc. has announced the publication of findings from the pivotal Phase 2 FOENIX*-CCA2 clinical trial of futibatinib in The New England Journal of Medicine (NEJM) on January 19, 2023. The trial demonstrated substantial clinical benefits of futibatinib in patients previously treated for FGFR2 fusion/rearrangement-positive intrahepatic cholangiocarcinoma (iCCA). The results revealed an objective response rate of 42% upon independent review, with a median response duration of 9.7 months. Futibatinib exhibited enduring responses and survival rates that exceeded historical chemotherapy data for previously treated iCCA patients.
  • In October 2022, Invitae has formed a collaboration with AstraZeneca, leveraging Invitae’s Ciitizen natural history data for a comprehensive examination involving retrospective and prospective studies of individuals diagnosed with cholangiocarcinoma, a rare cancer affecting the bile duct. This partnership facilitates the exchange of meticulously curated, patient-consented data sourced from the Cholangiocarcinoma Foundation (CCF), a prominent patient advocacy group dedicated to discovering a cure and enhancing the lives of individuals impacted by cholangiocarcinoma.
  • In November 2022, The FDA has awarded orphan drug designation for ZB131 in the treatment of cholangiocarcinoma, as confirmed by the drug’s manufacturer. ZB131, developed by ZielBio, is a monoclonal antibody that demonstrates high affinity and specificity for cancer-specific plectin.

 

Cholangiocarcinoma Overview

A type of cancer known as cholangiocarcinoma develops in the cells lining the bile duct, which serves as the liver’s drainage channel for bile. Bile duct cancer, another name for this rare type of cancer, usually affects adults over 50, however it can strike anyone at any age.

 

Get a Free Sample PDF Report to know more about Cholangiocarcinoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/cholangiocarcinoma-cca-pipeline-insight

 

Emerging Cholangiocarcinoma Drugs Under Different Phases of Clinical Development Include:

  • WM-S1: Well Marker Bio
  • STP-705: Sirnaomics
  • KIN-3248: Kinnate Biopharma
  • MIV-818: Medivir
  • E7090: Eisai Co., Ltd.
  • TT-00420: TransThera Biosciences
  • HMPL-453: Hutchison Medipharma Limited
  • ABC294640: RedHill Biopharma Limited
  • CTX-009: Compass Therapeutics
  • KEYTRUDA (pembrolizumab): Merck Sharp & Dohme
  • Tasurgratinib (E7090): Eisai
  • LENVIMA (lenvatinib): Eisai and Merck & Co
  • Zanidatamab: Zymeworks and BeiGene
  • Melphalan: Decalth Systems
  • Derazantinib: Basilea Pharmaceutica
  • Imfinzi (durvalumab): AstraZeneca
  • TAS-120 (futibatinib): Taiho Oncology

 

Cholangiocarcinoma Route of Administration

Cholangiocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.

 

Cholangiocarcinoma Molecule Type

Cholangiocarcinoma Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy 

 

Cholangiocarcinoma Pipeline Therapeutics Assessment

  • Cholangiocarcinoma Assessment by Product Type
  • Cholangiocarcinoma By Stage and Product Type
  • Cholangiocarcinoma Assessment by Route of Administration
  • Cholangiocarcinoma By Stage and Route of Administration
  • Cholangiocarcinoma Assessment by Molecule Type
  • Cholangiocarcinoma by Stage and Molecule Type

 

DelveInsight’s Cholangiocarcinoma Report covers around 60+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Cholangiocarcinoma product details are provided in the report. Download the Cholangiocarcinoma pipeline report to learn more about the emerging Cholangiocarcinoma therapies

 

Some of the key companies in the Cholangiocarcinoma Therapeutics Market include:

Key companies developing therapies for Cholangiocarcinoma are –  Merck KGaA, Eisai Inc., Janssen Research & Development, LLC, 3D Medicines, Basilea Pharmaceutica, Hutchison Medipharma Limited, Jiangsu HengRui Medicine, TransThera Sciences, RedHill Biopharma, Eli Lilly and Company, Elevation oncology, Senhwa Biosciences, InnoCare Pharma, Genoscience Pharma, Intensity therapeutics, Elucida Oncology, GlaxoSmithKline, Verismo Therapeutics, Sirnaomics, Toray Industries, Inc, Kinnate Biopharma, Boehringer Ingelheim, Wellmarker Bio, Arbele Limited, NGM Biopharmaceuticals, Inc., Elicio Therapeutics, Xencor, Inc., Celon Pharma SA, and others.

 

Cholangiocarcinoma Pipeline Analysis:

The Cholangiocarcinoma pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Cholangiocarcinoma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cholangiocarcinoma Treatment.
  • Cholangiocarcinoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Cholangiocarcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cholangiocarcinoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Cholangiocarcinoma drugs and therapies

 

Cholangiocarcinoma Pipeline Market Drivers

  • Increasing Incidence of Cholangiocarcinoma, increasing R&D Activities, increasing Awareness are some of the important factors that are fueling the Cholangiocarcinoma Market.

 

Cholangiocarcinoma Pipeline Market Barriers

  • However, high cost of drugs, high Incidence of adverse events and other factors are creating obstacles in the Cholangiocarcinoma Market growth.

 

Scope of Cholangiocarcinoma Pipeline Drug Insight    

  • Coverage: Global
  • Key Cholangiocarcinoma Companies: Well Marker Bio, Sirnaomics, Kinnate Biopharma, Medivir, Eisai Co., Ltd., TransThera Biosciences, Hutchison Medipharma Limited, RedHill Biopharma Limited, Compass Therapeutics, Merck Sharp & Dohme, Eisai, Merck & Co, Zymeworks and BeiGene, Decalth Systems, Basilea Pharmaceutica, AstraZeneca, Taiho Oncology, and others
  • Key Cholangiocarcinoma Therapies: WM-S1, STP-705, KIN-3248, MIV-818, E7090, TT-00420, HMPL-453, ABC294640, CTX-009, KEYTRUDA (pembrolizumab), Tasurgratinib (E7090), LENVIMA (lenvatinib), Zanidatamab, Melphalan, Derazantinib, Imfinzi (durvalumab), TAS-120 (futibatinib), and others
  • Cholangiocarcinoma Therapeutic Assessment: Cholangiocarcinoma current marketed and Cholangiocarcinoma emerging therapies
  • Cholangiocarcinoma Market Dynamics: Cholangiocarcinoma market drivers and Cholangiocarcinoma market barriers 

 

Request for Sample PDF Report for Cholangiocarcinoma Pipeline Assessment and clinical trials

 

Table of Contents

1. Cholangiocarcinoma Report Introduction

2. Cholangiocarcinoma Executive Summary

3. Cholangiocarcinoma Overview

4. Cholangiocarcinoma- Analytical Perspective In-depth Commercial Assessment

5. Cholangiocarcinoma Pipeline Therapeutics

6. Cholangiocarcinoma Late Stage Products (Phase II/III)

7. Cholangiocarcinoma Mid Stage Products (Phase II)

8. Cholangiocarcinoma Early Stage Products (Phase I)

9. Cholangiocarcinoma Preclinical Stage Products

10. Cholangiocarcinoma Therapeutics Assessment

11. Cholangiocarcinoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Cholangiocarcinoma Key Companies

14. Cholangiocarcinoma Key Products

15. Cholangiocarcinoma Unmet Needs

16 . Cholangiocarcinoma Market Drivers and Barriers

17. Cholangiocarcinoma Future Perspectives and Conclusion

18. Cholangiocarcinoma Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432, Las Vegas NV S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cholangiocarcinoma Pipeline Drugs Analysis Report(2023 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Merck KGaA, Eisai, Janssen Research, 3D Medicines, Basilea Pharma

MDSA Ventures Invests In Innovative Defense Tech Start Up

MDSA Ventures Invests In Innovative Defense Tech Start Up
Combat Bound LLC, a Department of Defense (DoD) technology company, is thrilled to announce the recent strategic partnership and investment from MDSA Aerospace (MDSA). This collaboration marks a significant milestone for both organizations and is poised to drive advancements in defense technology and capabilities.

This investment will advance the go-to-market strategy for the patent-pending electronic warfare Puca system, and the patent-pending RSCU litter combat extraction system. Both technologies have received recent military contract awards and in-field testing engagements.

Headquartered in Exton, PA, MDSA Aerospace provides Project Management, Mechanical Design and Structural Analysis Services, Electrical Engineering Services, DoD and FAA Flight Clearance Support, Avionics System Integration Support, and Technical Publications Development for Government and Commercial customers in the Aerospace, Aviation, Unmanned Systems, and Training and Simulation sectors.

Combat Bound CEO, Emil Reynolds, expressed, “We are delighted to welcome Steven Matthews, CEO, and MDSA Aerospace as strategic partners. Their investment and engineering expertise will undoubtedly propel the Puca and RSCU systems towards operational readiness and production, enabling us to meet the evolving needs of defense and security forces, both domestically and internationally.”

For media inquiries or further information, please contact:

Combat Bound LLC

757-263-0395

info@combatbound.com

www.combatbound.com

Media Contact
Company Name: Combat Bound
Contact Person: Media Contact
Email: Send Email
Country: United States
Website: http://combatbound.com

Ischemic Stroke Pipeline Analysis, 2023 Updates | Latest FDA, EMA, and PMDA Approvals | Bristol-Myers Squibb, NuvOX Pharma, Simcere Pharma, Genentech, Biogen, Athersys, Inc., Tarveda Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Ischemic Stroke pipeline constitutes 50+ key companies continuously working towards developing 55+ Ischemic Stroke treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Ischemic Stroke Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Ischemic Stroke Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ischemic Stroke Market.

 

Some of the key takeaways from the Ischemic Stroke Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Ischemic Stroke treatment therapies with a considerable amount of success over the years. 
  • Ischemic Stroke companies working in the treatment market are TargED Biopharmaceuticals, Saillant Therapeutics, AbbVie, Revalesio Corporation, Biogen, Acticor Biotech, ZZ Biotech, GNT Pharma, Athersys, Inc., Acticor Biotech, Lumosa Therapeutics, Avilex Pharma, and others, are developing therapies for the Ischemic Stroke treatment 
  • Emerging Ischemic Stroke therapies in the different phases of clinical trials are- Microlyse, ST-01, Elezanumab, RNS60, BIIB131, Glenzocimab, 3K3A-APC, Nelonemdaz, MultiStem, Glenzocimab, LT3001, AVLX-144, and others are expected to have a significant impact on the Ischemic Stroke market in the coming years.   
  • In July 2022, ACTICOR BIOTECH disclosed that its drug candidate, glenzocimab, obtained “PRIority Medicines” designation from the European Medicines Agency (EMA) for treating stroke patients. This designation facilitates Acticor Biotech in enhancing engagements and securing preliminary discussions with regulatory bodies to solidify the clinical development strategy for glenzocimab in stroke treatment.
  • In July 2022, NervGen Pharma revealed that a groundbreaking preclinical study conducted by the University of Cincinnati and Case Western Reserve University (CWRU) has been published in the scientific journal Cell Reports. This study showcases the effectiveness of NervGen’s unique drug, NVG-291-R, in facilitating nervous system repair and notable functional recuperation in a mouse model of severe ischemic stroke. Notably, the treatment demonstrated significant recovery benefits even when initiated up to 7 days after the onset of the stroke.
  • In June 2022, Pharmazz Inc has unveiled encouraging top-line outcomes from its Phase III clinical trial assessing sovateltide’s efficacy in treating acute ischemic stroke. The results highlighted a notable increase, at the 90-day mark, in the number of participants showing a significant improvement of 2 points or more on the modified Rankin Score (mRS), a substantial reduction in the median score on the mRS, and a considerable decrease in the number of individuals displaying an improvement of 6 or more points on the NIHSS Level of Consciousness (1A)
  • In February 2022, Acticor Biotech disclosed encouraging results derived from its Phase Ib/IIa ACTIMIS clinical trial evaluating glenzocimab as an adjunctive therapy alongside the standard care for acute ischemic stroke (AIS) patients. The findings indicated the trial successfully achieved its primary objective by confirming the favorable safety profile of glenzocimab.
  • In February 2022, Bayer revealed that the U.S. Food and Drug Administration (FDA) has provided Fast Track Designation for its experimental drug asundexian (BAY2433334) concerning its potential application as a treatment for secondary prevention among patients who have experienced a non-cardioembolic ischemic stroke.
  • In May 2022, Athersys, Inc. disclosed that its collaborator, HEALIOS K.K. (Healios), released the key findings from its Japan-based ischemic stroke study, TREASURE. The study revealed notable improvements in predetermined functional measures associated with “independence” and positive outcomes such as mRS ≤2, Barthel Index ≥95, and Global Recovery linked to MultiStem treatment. However, the primary endpoint of achieving an excellent outcome at 90 days did not demonstrate statistical significance in the overall population. Importantly, there were no substantial differences observed in safety outcomes, including mortality and life-threatening adverse events, between the treatment and placebo groups.

 

Ischemic Stroke Overview

An ischemic stroke, also known as a brain attack, happens when a blood artery in the brain breaks or when something stops the blood supply to a portion of the brain. Either way, certain brain regions suffer harm or even die. A stroke can result in death, long-term incapacity, or permanent brain damage.

 

Get a Free Sample PDF Report to know more about Ischemic Stroke Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/ischemic-stroke-pipeline-insight

 

Emerging Ischemic Stroke Drugs Under Different Phases of Clinical Development Include:

  • Microlyse: TargED Biopharmaceuticals
  • ST-01: Saillant Therapeutics
  • Elezanumab: AbbVie
  • RNS60: Revalesio Corporation
  • BIIB131: Biogen
  • Glenzocimab: Acticor Biotech
  • 3K3A-APC: ZZ Biotech
  • Nelonemdaz: GNT Pharma
  • MultiStem: Athersys, Inc.
  • Glenzocimab: Acticor Biotech
  • Elezanumab: AbbVie
  • LT3001: Lumosa Therapeutics
  • AVLX-144: Avilex Pharma

 

Ischemic Stroke Route of Administration

Ischemic Stroke pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Ischemic Stroke Molecule Type

Ischemic Stroke Products have been categorized under various Molecule types, such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Ischemic Stroke Pipeline Therapeutics Assessment

  • Ischemic Stroke Assessment by Product Type
  • Ischemic Stroke By Stage and Product Type
  • Ischemic Stroke Assessment by Route of Administration
  • Ischemic Stroke By Stage and Route of Administration
  • Ischemic Stroke Assessment by Molecule Type
  • Ischemic Stroke by Stage and Molecule Type

 

DelveInsight’s Ischemic Stroke Report covers around 55+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Ischemic Stroke product details are provided in the report. Download the Ischemic Stroke pipeline report to learn more about the emerging Ischemic Stroke therapies

 

Some of the key companies in the Ischemic Stroke Therapeutics Market include:

Key companies developing therapies for Ischemic Stroke are – Bristol-Myers Squibb, NuvOX Pharma, Simcere Pharmaceutical Co., Ltd., Genentech, Inc., NoNO Inc., Pharming Technologies B.V., Biogen, Athersys, Inc., Tarveda Therapeutics, Nanjing Yoko Biomedical Co., Ltd., TrueBinding, Inc., GNT Pharma, Roche, DiaMedica Therapeutics Inc, aptaTargets, Avilex Pharma, Lumosa Therapeutics, NC Medial Research Inc, Acticor Biotech, Meridigen Biotech Co., Prolong Pharmaceuticals, SanBio, ZZ Biotech, Revalesio, Stemedica Cell Technologies, StemCyte, Ninnion, Algernon Pharmaceuticals, Primary Peptides, TMS, Tasly Pharmaceutical, Pharmazz and others.

 

Ischemic Stroke Pipeline Analysis:

The Ischemic Stroke pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Ischemic Stroke with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ischemic Stroke Treatment.
  • Ischemic Stroke key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Ischemic Stroke Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ischemic Stroke market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Ischemic Stroke drugs and therapies

 

Ischemic Stroke Pipeline Market Drivers

  • Rising incidence of Acute Ischemic Stroke, increasing prevalence of lifestyle associated disorders such as diabetes and hypertension, rising geriatric population are some of the important factors that are fueling the Ischemic Stroke Market.

 

Ischemic Stroke Pipeline Market Barriers

  • However, challenges associated with the clinical research, challenges with the diagnosis of AIS and other factors are creating obstacles in the Ischemic Stroke Market growth.

 

Scope of Ischemic Stroke Pipeline Drug Insight    

  • Coverage: Global
  • Key Ischemic Stroke Companies: TargED Biopharmaceuticals, Saillant Therapeutics, AbbVie, Revalesio Corporation, Biogen, Acticor Biotech, ZZ Biotech, GNT Pharma, Athersys, Inc., Acticor Biotech, Lumosa Therapeutics, Avilex Pharma, and others
  • Key Ischemic Stroke Therapies: Microlyse, ST-01, Elezanumab, RNS60, BIIB131, Glenzocimab, 3K3A-APC, Nelonemdaz, MultiStem, Glenzocimab, LT3001, AVLX-144, and others
  • Ischemic Stroke Therapeutic Assessment: Ischemic Stroke current marketed and Ischemic Stroke emerging therapies
  • Ischemic Stroke Market Dynamics: Ischemic Stroke market drivers and Ischemic Stroke market barriers 

 

Request for Sample PDF Report for Ischemic Stroke Pipeline Assessment and clinical trials

 

Table of Contents

1. Ischemic Stroke Report Introduction

2. Ischemic Stroke Executive Summary

3. Ischemic Stroke Overview

4. Ischemic Stroke- Analytical Perspective In-depth Commercial Assessment

5. Ischemic Stroke Pipeline Therapeutics

6. Ischemic Stroke Late Stage Products (Phase II/III)

7. Ischemic Stroke Mid Stage Products (Phase II)

8. Ischemic Stroke Early Stage Products (Phase I)

9. Ischemic Stroke Preclinical Stage Products

10. Ischemic Stroke Therapeutics Assessment

11. Ischemic Stroke Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Ischemic Stroke Key Companies

14. Ischemic Stroke Key Products

15. Ischemic Stroke Unmet Needs

16 . Ischemic Stroke Market Drivers and Barriers

17. Ischemic Stroke Future Perspectives and Conclusion

18. Ischemic Stroke Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ischemic Stroke Pipeline Analysis, 2023 Updates | Latest FDA, EMA, and PMDA Approvals | Bristol-Myers Squibb, NuvOX Pharma, Simcere Pharma, Genentech, Biogen, Athersys, Inc., Tarveda Therapeutics

The Blue Light Glasses Protect Eyes from the Impact of the Screen World

“At Vooglam, we believe that every pair of glasses is more than just an accessory. It is an extension of your personality and your window to the world. No matter who you are or where you are, this Halloween, let Vooglam be with you Reveal your true self.”
Explore the world of blue light blocking glasses with Vooglam. Learn how these innovative lenses protect your eyes from digital strain, enhance sleep patterns, and fit your style. Vooglam combines health and fashion in eyewear, offering affordable, high-quality blue light filtering glasses. Perfect for office workers, gamers, and digital device users.

For office workers, spending approximately 1,700 hours per year immersed in electronic screens has become the norm. We often find ourselves engrossed in digital device screens for hours on end, whether it’s checking early morning emails or indulging in a late-night Netflix binge. The next exciting post on Instagram or the next entertaining video on TikTok is always just a click away. But have you ever considered the long-term effects of prolonged exposure to blue light on your eyes and overall health?

Doctors and researchers have provided a clear and concise answer to this question, which is of primary concern to many: prolonged exposure to a blue light environment poses the risk of digital eye strain.

What is blue light, and how does it affect us?

The visible light spectrum consists of light waves ranging from red to purple, and among these waves is blue light. Evidence suggests that blue light is associated with various issues, from eye strain to even blindness. In fact, most electronic screens, including those of our beloved devices, are equipped with LED screens that emit high-energy, short-wavelength blue light, which can have adverse effects on our health. Quoting the American Optometric Association, they state, “Digital eye strain is a group of vision-related problems resulting from the prolonged use of computers, tablets, e-readers, and cell phones. These problems can include, but are not limited to, blurred vision, dry eyes, headaches, and even neck pain.” Especially concerning is the blue light emitted in low-light or dark conditions, which can disrupt sleep patterns and potentially harm the retina. This provides a compelling reason to study how to avoid and minimize the interference of blue light in our lives and health.

After scientists and the general public became aware of the potential hazards of blue light, a product emerged to combat its effects on individuals—blue light blocking glasses. This remarkable product, professionally designed, has the ability to filter out most harmful blue light emitted from electronic device screens, providing an extra layer of protection for your eyes. Imagine being able to enjoy your favorite content without worrying about eye fatigue or disruptions to your sleep patterns. The advent of blue light blocking glasses has made all of this possible.

 

How do blue light blocking glasses work, and why are they effective?

Serving as a barrier between your eyes and electronic screens, they employ special coatings to reflect and filter the harmful effects of blue light, protecting your eyes from the direct impact and reducing eye fatigue. By minimizing the blue light that reaches your eyes directly, these lenses offer protection for virtually everyone, whether you’re a student burning the midnight oil, a parent catching up on emails after the kids are in bed, or an avid enthusiast of video games and various series.

Before choosing blue light-blocking glasses, consider whether you can control your screen usage to mitigate the potential health risks associated with blue light exposure. For most people, the answer is clear – it’s time to consider a pair of blue light-blocking glasses to protect yourself.

If you’re in need of blue light-blocking glasses for immediate protection, we recommend an excellent and cost-effective brand – Vooglam. Vooglam is a beloved and trusted brand in the eyewear industry, with a strong focus on eye health. Their products are durable, flexible, and comfortable. As a brand with a mature and professional online sales channel, you won’t need to go through complicated steps to customize your blue light lenses – everything you need is at your fingertips.

Whether you order from their website or app, simply select “Blue Light Blocking” in the lens options during the ordering process. Vooglam’s blue light-blocking lenses are compatible with prescription glasses as well as fashionable styles for those looking to change their look. While many eyewear companies offer blue light-blocking lens options in their fitting choices, Vooglam stands out for its exceptional quality and reputation. Additionally, Vooglam provides hundreds of budget-friendly, high-quality choices. As a leading brand in fashion frames, their TAGs always lead the way in the next fashion trend on social media.

Concerned that your frame won’t suit you?

As a recommended brand that deeply considers its customers, Vooglam has introduced an AR try-on feature on its app. With just a camera-equipped smartphone, you can try hundreds of different styles of glasses. These unique frames suit all face shapes. Why spend money on ordering glasses online without trying them first? Consider Vooglam’s AR try-on solution to select the perfect glasses for you.

A Wise Shopping Choice:

Generally, blue light-blocking lenses tend to be more expensive than regular lens materials due to their unique advantages and specialized functionality. However, Vooglam’s promotional activities make these professional lenses more affordable. No matter where you come across this promotion, you shouldn’t miss out on this fantastic buying opportunity.

​You can find options for anti-blue light prescription lenses on Vooglam’s eyewear details online shop page. If you are already a Vooglam customer or have received information notifications from Vooglam, just click on the latest promotion link to view the details. It’s never too late to take care of your eye health. Vooglam’s cost-effective anti-blue light lenses protect your eye health.

Media Contact
Company Name: Vooglam
Contact Person: Byron
Email: Send Email
Phone: +13023097808
Address:5900 BALCONES DRIVE SUITE 100
City: Austin
State: Texas
Country: United States
Website: https://www.vooglam.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Blue Light Glasses Protect Eyes from the Impact of the Screen World

AV Access Introduces iDock C10 KVM Switch Docking Station, Empowering Users to Create a Dynamic Home Workstation

“AV Access introduces the iDock C10 4K KVM switch docking station to cater to the growing number of individuals working from home. As the demand for multiple PCs and monitors rises, this innovative device enables users to effortlessly manage two PCs, two 4K monitors, and numerous peripherals simultaneously.”
AV Access presents the iDock C10, a groundbreaking integration of a dual monitor KVM switch and a 12-in-1 docking station. This innovative device allows users to effortlessly control their desktop or laptop with two monitors and multiple peripherals, enhancing productivity in office work, learning, and gaming.

AV Access, a leading provider of Pro AV and AV over IP solutions, is excited to unveil the iDock C10 KVM switch docking station as the latest addition to its impressive lineup of KVM switches. With its dual monitor design, extensive peripheral connectivity, full-featured USB-C input port, remarkable ultra-high refresh rates, and other exceptional features, iDock C10 is the perfect solution for office work, gaming, and learning.

4K Dual Monitor KVM Switch with a Versatile 12-in-1 Docking Station

“Today, an increasing number of individuals working from home find themselves in need of multiple PCs and monitors, as well as various peripheral devices such as keyboards, microphones, and SD cards. Our new KVM switch docking station is specifically tailored to meet the requirements of these professionals, including video editors, graphic designers, and avid gamers. It simplifies home office setups, reduces the need for additional peripherals, and significantly enhances productivity,” explained Bill Liao, CTO of AV Access.

The iDock C10 4K dual monitor KVM switch features a USB-C input port (supporting multi-stream transport) for a laptop, along with an integrated HDMI + DisplayPort + USB-B input port for a desktop computer. Furthermore, users can take advantage of abundant peripheral connectivity, including 3x USB 3.0, 2x USB 2.0, 1x USB-C, 1x SD card, 1x LAN, 1x Toslink out, 1x 3.5mm headset, and two HDMI outputs, allowing seamless integration of multiple devices.

Immersive High Refresh Rate & Fast Switching

The iDock C10 KVM switch supports ultra-high refresh rates, such as 1080P@240Hz/165Hz/144Hz/120Hz and 2560×1440@144Hz/120Hz, ensuring smooth switching between high-speed racing game sources.

Moreover, equipped with a full-featured USB-C port, this powerful 4K KVM switch offers users the ability to transfer data, audio, video, and power using just a single USB-C cable. Dual 4K UHD videos can be inputted, enabling the transmission of large data volumes at up to 5Gbp/s while simultaneously charging the laptop with up to 60W.

Switching between two PC sources is effortless and swift, thanks to the automatic PC wake-up and EDID emulation features of the 4K KVM switch. Users can effortlessly switch between their devices in just 2-3 seconds.

“Our highly sought-after KVM switch docking station is now available for purchase on our official site at the competitive price of $259.99. It is an essential tool for seamlessly switching between your gaming PC and workstation,” added Bill.

About AV Access

AV Access is the world’s professional manufacturer of advanced Pro AV and AV over IP products, which include extenders, splitters, switchers, matrixes, AV over IP codecs, etc. Since establishment, it has long been our mission to offer ultimate audiovisual experience to the masses by delivering quality-assured and well-designed AV products at honest pricing. We will continue to develop more innovative products and solutions in the fields of smart home, corporate, education, retail, entertainment, health care, etc. Strong R&D, powerful supply chain and excellent management team make AV Access be qualified as your faithful partner! Learn more by visiting www.avaccess.com.

Media Contact
Company Name: Actions Global (US) Inc
Contact Person: Shane Jiang
Email: Send Email
Phone: +1-866-629-3923
Address:100 N HOWARD ST STE R
City: City of Spokane
State: Washington 99201
Country: United States
Website: https://www.avaccess.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: AV Access Introduces iDock C10 KVM Switch Docking Station, Empowering Users to Create a Dynamic Home Workstation